{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:18:51Z","timestamp":1775078331277,"version":"3.50.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The factors associated with health-related quality of life in patients with glioma remain unclear; particularly, the impact of symptoms on quality of life has not been studied comprehensively. This study aims to document the quality of life of patients with glioma and clarify the impact of symptoms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this cross-sectional study, participants were recruited from patients at The University of Tokyo Hospital and from patients who were registered at the Japan Brain Tumor Alliance. We included adult patients with World Health Organization grade II\u2013IV glioma and excluded those with disturbances of consciousness or aphasia. We used the European Organization for Research and Treatment of Cancer QLQ-C30 and BN20 to evaluate quality of life and the symptoms. Multiple regression analyses were performed to investigate the impact of symptoms on European Organization for Research and Treatment of Cancer global health status and QLQ-C30 social functioning. In addition, we performed univariate subgroup analyses classified by World Health Organization grade and history of chemotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>This study included 76 patients. Seven symptoms occurred in more than 50% of the patients: fatigue, future uncertainty, drowsiness, communication deficit, financial difficulties, motor dysfunction and weakness of legs. Multiple regression analyses showed that insomnia affected their global health status, and appetite loss, financial difficulties and motor dysfunction were significantly related to their social functioning. In subgroup analysis, the number of symptom subscales that were significantly related to global health status and social functioning was larger in World Health Organization grade II patients compared with grade III\/IV patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In addition to neurological deficits, symptoms were associated with poor quality of life in patients with glioma. This study provided the basis on further investigation of usefulness of symptom evaluation on quality of life improvement.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyaa068","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T11:18:25Z","timestamp":1588159105000},"page":"990-998","source":"Crossref","is-referenced-by-count":28,"title":["Factors associated with health-related quality of life in patients with glioma: impact of symptoms and implications for rehabilitation"],"prefix":"10.1093","volume":"50","author":[{"given":"Shigeko","family":"Umezaki","sequence":"first","affiliation":[{"name":"Department of Rehabilitation Medicine, The University of Tokyo Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5489-2751","authenticated-orcid":false,"given":"Yusuke","family":"Shinoda","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, The University of Tokyo Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akitake","family":"Mukasa","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Tokyo Hospital, Tokyo, Japan"},{"name":"Department of Neurosurgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Tokyo Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsaku","family":"Takayanagi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Tokyo Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Medical Research and Management for Musculoskeletal Pain, 22nd Century Medical & Research Center, Faculty of Medicine, The University of Tokyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisato","family":"Tagawa","sequence":"additional","affiliation":[{"name":"Japan Brain Tumor Alliance, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Haga","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, The University of Tokyo Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"2020090501523252700_ref1","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2001.19.20.4037","article-title":"Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients","volume":"19","author":"Klein","year":"2001","journal-title":"J Clin Oncol"},{"key":"2020090501523252700_ref2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/neuonc\/2.4.221","article-title":"Effect of disease burden on health-related quality of life in patients with malignant gliomas","volume":"2","author":"Osoba","year":"2000","journal-title":"Neuro Oncol"},{"key":"2020090501523252700_ref3","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1200\/JCO.2014.60.3217","article-title":"Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma","volume":"33","author":"Taphoorn","year":"2015","journal-title":"J Clini Oncol"},{"key":"2020090501523252700_ref4","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s11060-017-2479-8","article-title":"Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma","volume":"133","author":"Field","year":"2017","journal-title":"J Neurooncol"},{"key":"2020090501523252700_ref5","first-page":"975","article-title":"Quality of life in the GLARIUS trial randomizeing bevacizumab\/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma","volume":"20","author":"Sch\u00e4fer","year":"2018","journal-title":"Neurooncol"},{"key":"2020090501523252700_ref6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00701-013-1930-7","article-title":"Predictors of health-related quality of life in neurosurgical brain tumor patients: focus on patient-centered perspective","volume":"156","author":"Bunevicius","year":"2014","journal-title":"Acta Neurochir"},{"key":"2020090501523252700_ref7","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s00415-014-7273-3","article-title":"Quality of life and brain tumors: what beyond the clinical burden?","volume":"261","author":"Giovagnoli","year":"2014","journal-title":"J Neurol"},{"key":"2020090501523252700_ref8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11060-012-1024-z","article-title":"Factors associated with long-term functional outcomes, psychological sequelae and quality of life in persons after primary brain tumour","volume":"111","author":"Khan","year":"2013","journal-title":"J Neurooncol"},{"key":"2020090501523252700_ref9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11060-009-9939-8","article-title":"Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice","volume":"95","author":"Budrukker","year":"2009","journal-title":"J Neurooncol"},{"key":"2020090501523252700_ref10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1015728825642","article-title":"Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional stress, and existential issues","volume":"57","author":"Pelletier","year":"2002","journal-title":"J Neurooncol"},{"key":"2020090501523252700_ref11","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/jjco\/hyv115","article-title":"Health-related quality of life in long-term survivors with grade II gliomas: the contributions of disease recurrence and Karnofsky performance status","volume":"45","author":"Okita","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"2020090501523252700_ref12","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00520-006-0080-3","article-title":"The relationship between function, quality of life and coping in patients with low-glade glioma","volume":"14","author":"Gustafasson","year":"2006","journal-title":"Support Care Cancer"},{"key":"2020090501523252700_ref13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11060-005-7020-9","article-title":"Prospective study of quality of life in adults with newly diagnosed high-grade gliomas","volume":"76","author":"Brown","year":"2006","journal-title":"J Neurooncol"},{"key":"2020090501523252700_ref14","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/PHM.0000000000000756","article-title":"Health-related quality of life and cancer-related symptoms during interdisciplinary outpatient rehabilitation for malignant brain tumor","volume":"96","author":"McCarty","year":"2017","journal-title":"Am J Phys Med Rehabil"},{"key":"2020090501523252700_ref15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00401-018-1808-0","article-title":"cIMPACT-NOW update 1: not otherwise specified (NOS) and not elsewhere classified (NEC)","volume":"135","author":"Louis","year":"2018","journal-title":"Acta Neuropathol"},{"key":"2020090501523252700_ref16","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"2020090501523252700_ref17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.1984.2.3.187","article-title":"Karnofsky performance status revisited: reliability, validity, and guidelines","volume":"2","author":"Schag","year":"1984","journal-title":"J Clin Oncol"},{"key":"2020090501523252700_ref18","volume-title":"Questionnaires","author":"European Organisation for Research and Treatment of Cancer","year":"2019"},{"key":"2020090501523252700_ref19","volume-title":"The EORTC QLQ-C30 and BN-20 Scoring Manual","author":"Fayers","edition":"3rd edn"},{"key":"2020090501523252700_ref20","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ejca.2010.01.012","article-title":"An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients","volume":"46","author":"Taphoorn","year":"2010","journal-title":"Eur J Cancer"},{"key":"2020090501523252700_ref21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1215\/15228517-2008-093","article-title":"Quality of life in adults with brain tumors: current knowledge and future directions","volume":"11","author":"Liu","year":"2009","journal-title":"Neuro Oncol"},{"key":"2020090501523252700_ref22","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00520-011-1288-4","article-title":"Prospective assessment of health-related quality of life in patients with low-grade glioma: a single-center experience","volume":"20","author":"Yavas","year":"2012","journal-title":"Support Care Cancer"},{"key":"2020090501523252700_ref23","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/ptj\/pzz180","article-title":"Effectiveness of physical therapy-and occupational therapy-based rehabilitation in people who have glioma and are undergoing active anticancer treatment: single-blind, randomized controlled trial","volume":"100","author":"Hansen","year":"2020","journal-title":"Phys Ther"},{"key":"2020090501523252700_ref24","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fneur.2019.00212","article-title":"et\u00a0al","volume":"10","author":"Gabel","year":"2019","journal-title":"Front Neurol"},{"key":"2020090501523252700_ref25","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S1470-2045(05)70432-0","article-title":"Health-related quality of life in patients with glioblastoma: a randomized controlled trial","volume":"6","author":"Taphoorn","year":"2005","journal-title":"Lancet Oncol"},{"key":"2020090501523252700_ref26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1023\/A:1023900802254","article-title":"Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma","volume":"63","author":"Walker","year":"2003","journal-title":"J Neurooncol"},{"key":"2020090501523252700_ref27","first-page":"1475","article-title":"Reporting of patient-reported health-related quality of life in adults with diffuse low-grade glioma: a systematic review","volume":"18","author":"Fountain","year":"2016","journal-title":"Neuro Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/50\/9\/990\/33717347\/hyaa068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/50\/9\/990\/33717347\/hyaa068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T05:52:57Z","timestamp":1599285177000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/50\/9\/990\/5850048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,6,2]]},"published-print":{"date-parts":[[2020,9,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaa068","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,6,2]]}}}